Market Overview

Array BioPharma Touts Approval Of Melanoma Drug

Array BioPharma Touts Approval Of Melanoma Drug
Related ARRY
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut
Traders Are Confused- Cramer's Mad Money (12/10/18) (Seeking Alpha)

Array Biopharma Inc (NASDAQ: ARRY) shares were halted Wednesday after the Food and Drug Administration approved its drug candidate. 

What Happened 

The FDA approved Braftovi in combination with Mektovi for patients with unresectable or metastatic BRAF-mutant melanoma.

Array spiked 3.1 percent before being halted around 12:52 p.m. ET. Shares were volatile, last down about 2 percent after resuming trading at 2:15 p.m. Wednesday.

Why It’s Important

The therapy is thought to have an expansive market opportunity, as nearly half of patients with metastatic melanoma have the BRAF mutation.

“As presented at ASCO, BRAFTOVI [and] MEKTOVI is the first targeted treatment to demonstrate over 30 months median overall survival in a Phase 3 trial,” Array CEO Ron Squarer said in a press release. “These products represent a new standard of care for BRAF-mutant melanoma patients.”

What’s Next

The combination therapy is immediately available for order through select specialty pharmacies.

Array is in the process of submitting its trial results to global regulatory authorities.

Related Links:

Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Posted-In: BraftoviBiotech News FDA General Best of Benzinga


Related Articles (ARRY)

View Comments and Join the Discussion!

Mid-Afternoon Market Update: U.S. Stocks Turn Negative; Cara Therapeutics Shares Spike Higher

Walgreens Boots Alliance Q3 Earnings Preview